

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2013

PART-I

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Income from operations	68741	56588	53333	176917	147434	212395
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	186	107	103	420	327	494
	Total Income from operations (net)	68927	56695	53436	177337	147761	212889
2	Expenses						
	a. Cost of materials consumed	24473	28149	26080	81011	66468	89790
	b. Purchases of stock-in-trade	0		14	0	14	9
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1151	(10133)	(3972)	(19622)	(12124)	(10033)
	d. Employee benefits expense	5710	5615	4552	16628	13734	19120
	e. Depreciation and amortization expense	2327	2252	2036	6667	5663	7690
	f. Other Expenses	8814	8192	8531	25417	23707	31828
	Total Expenses	42475	34075	37241	110101	97462	138404
3	Profit from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	26452	22620	16195	67236	50299	74485
4	Other Income	791	3654	2232	9253	5067	4851
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	27243	26274	18427	76489	55366	79336
6	Finance Costs	35	39	44	115	116	178
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	27208	26235	18383	76374	55250	79158
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	27208	26235	18383	76374	55250	79158
10	Tax Expense	5306	5742	3959	16508	12291	18016
11	Net Profit from ordinary activities after Tax (9-10)	21902	20493	14424	59866	42959	61142
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	21902	20493	14424	59866	42959	61142
14	Share of profit / (loss) of associates	0	0	0	0	0	0
15	Minority Interest	0	0	0	0	0	0

16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	21902	20493	14424	59866	42959	61142
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						252673
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	16.50	15.44	10.86	45.10	32.36	46.06
	b) Diluted	16.50	15.44	10.86	45.10	32.36	46.06
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	16.50	15.44	10.86	45.10	32.36	46.06
	b) Diluted	16.50	15.44	10.86	45.10	32.36	46.06

PART-II - SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2013

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	63556194 47.88%	63532190 47.86%	63512190 47.85%	63556194 47.88%	63512190 47.85%	63512190 47.85%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 69178096 100% 52.12%	Nil 69202100 100%	Nil 69222100 100%	Nil 69178096 100% 52.12%	Nil 69222100 100%	Nil 69222100 100%

	Particulars	Quarter ended 31-12-2013
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	8
	Disposed off during the quarter	8
	Remaining unresolved at the end of the quarter	Nil

NOTES:

1. The above results for the period ended 31st December 2013, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 3rd February, 2014 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.

3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited Standalone Results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

Particulars	Quarter ended			Nine Months ended		Year Ended
	31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Forex Gain/(Loss)	(534)	3123	1565	6842	2491	1516

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/periods have also been regrouped or recasted, wherever necessary.

for Divi's Laboratories Limited

Place: Hyderabad
Date: 03-02-2014

Dr. Murali K. Divi
Chairman & Managing Director